Quantcast

Latest Factor VII Stories

2009-07-14 06:30:00

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical...

2009-07-13 07:00:00

BOSTON, July 13 /PRNewswire/ -- New data pooled from four large, "real world" post-marketing surveillance studies showed that sucrose-formulated recombinant factor VIII (rFVIII-FS) reduced bleeding and provided data regarding adverse events in more than 950 patients with mild-to-severe hemophilia A. Additionally, rates of inhibitor formation were reported in both previously treated and previously untreated patients. The data were presented at the XXII Congress of the International Society on...

2009-07-09 11:00:00

WAYNE, N.J., July 9 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals launched the BayCuff(TM) self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their caregivers. The centerpiece of the program is an adjustable cuff worn on the hand or arm that allows patients to practice the technique of self-injection without actually infusing themselves and helps caregivers learn to...

2009-04-17 07:30:00

BERKELEY, Calif., April 17 /PRNewswire/ -- In recognition of the 20th anniversary of World Hemophilia Day, Bayer HealthCare reaffirmed its commitment to the global hemophilia community by pledging euro 250,000 to the World Federation of Hemophilia (WFH). To mark this milestone, Bayer employees around the world will engage in activities to support the mission of this annual event - to increase awareness of and promote support for the needs of people living with hemophilia and other bleeding...

2009-02-12 07:30:00

IB1001, an Intravenous Recombinant Factor IX (rFIX) Product for the Treatment of Hemophilia B LAGUNA NIGUEL, Calif., Feb. 12 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., today announced the initiation of a Phase 1 clinical trial of IB1001, an intravenous (IV) recombinant Factor IX (rFIX) product for control and prevention of hemorrhagic episodes in patients with hemophilia B. It is estimated that the market for therapies to treat this disorder is in excess of $600 million. The...

2009-02-04 09:17:00

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A. Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene...

2008-11-13 15:00:29

MILWAUKEE, Nov. 13 /PRNewswire/ -- Investigators at Children's Research Institute, BloodCenter of Wisconsin's Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient's own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can be used to initiate clotting in hemophilia. This type of approach may work in the 30 to...

2008-11-13 09:00:36

BEIJING, Nov. 13 /PRNewswire/ -- Bayer Schering Pharmaceuticals, the leading pharmaceutical company in China and a global leader in hemophilia care, announced today a euro 1.5 million pledge to develop Hemophilia Treatment Centers (HTCs) throughout China. Over the next five years, Bayer's support will fund a variety of necessities, including equipment and supplies, patient programs, educational materials, medical training and nursing support. The Bayer China Hemophilia Treatment Center...

2008-11-12 12:00:31

NEW YORK, Nov. 12 /PRNewswire/ -- Val Bias, Chief Executive Officer of the National Hemophilia Foundation is featured in the November 2008 issue of Black Enterprise magazine in the "On the Move" section of the Powerplay Department. The department highlights African-American men and women who have been appointed to new management positions in the upper echelons of the corporate world. Recent announcements have included leadership posts at BET, MTV and Northrop Grumman. Black Enterprise...

2008-10-27 12:00:29

The European Medicines Agency (EMEA) has granted license approval to Bayer HealthCare LLC (Bayer) for its new sterile filling facility (SFF) on its Berkeley, Calif. campus. The approval closely follows authorization already given by the U.S. Food and Drug Administration in August 2008. Together, these licenses from the regulatory bodies ensure this state-of-the-art facility is ready to support the supply of Bayer's Kogenate(R) FS/ KOGENATE(R) Bayer (Antihemophilic Factor (Recombinant)) line...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related